Gilead said PSI-7977 will be more valuable in its hands because it has the infrastructure to bring the product to more people faster than Pharmasset.Gilead spent $11B on acquiring Pharmasset to get PSI-7977.The PSI-7977 patent runs out in 2029.
MKT The ASX can overlook its Telecomm small-caps. Here’s one diversified brand with an international footprint